Tositumomab and Iodine 131I Tositumomab
- Atc Codes:V10XA53
- CAS Codes:192391-48-3
- PHARMGKB ID:192391-48-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
North America
Canada: Bexxar; USA: Bexxar.
Drug combinations
Chemistry
Tositumomab: Immunoglobulin G~2a~ anti-(human antigen CD 20)(mouse monoclonal clone B1R1 γ2a-chain), disulfide with mouse monoclonal clone B1R1 λ~x~-chain, dimer. CAS-192391-48-3.
Pharmacologic Category
Other Antineoplastic Agents; Monoclonal Antibodies. (ATC-Code: V10XA53).
Mechanism of action
Tositumomab is a murine IgG~2a~ λ monoclonal antibody which binds to CD20 antigen, expressed on B-lymphocytes and on >90% of B-cell non-Hodgkin lymphomas. Administration results in depletion of CD20 positive cells.
Therapeutic use
Treatment of relapsed or refractory CD20 positive, low-grade, follicular, or transformed non-Hodgkin lymphoma.
Pregnancy and lactiation implications
Risk of fetal harm. Contraindicated in pregnancy and lactation.
Unlabeled use
Contraindications
Hypersensitivity to murine proteins or any component of the formulation. Pregnancy. Breast-feeding.
Warnings and precautions
Serious, including fatal, hypersensitivity reactions reported. Risk of severe thrombocytopenia and neutropenia. Do not use in >25% lymphoma marrow involvement and/or impaired bone marrow reserve.